(Q36681327)

15 August 2017

1 reference

title

The role of decitabine in the treatment of myelodysplastic syndromes (English)

1 reference

15 August 2017

2

Hagop Kantarjian

1 reference

15 August 2017

Guillermo Garcia-Manero

series ordinal

3

object named as

Guillermo Garcia-Manero

1 reference

15 August 2017

1

Ehab Atallah

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

65-73

1 reference

Proposals for the classification of the myelodysplastic syndromes

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Hypermethylation of tumor suppressor genes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Gametic imprinting in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Methylation profiling in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.65

21 January 2018

Identifiers

DOI

10.1517/14656566.8.1.65

1 reference

15 August 2017

1 reference